Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
101 EUR | -1.51% | +4.92% | +2.49% |
13:44 | UBS belässt Carl Zeiss Meditec auf 'Buy' - Ziel 130 Euro | DP |
23.04. | JPMorgan belässt Carl Zeiss Meditec auf 'Underweight' | DP |
Bewertung
Steuerjahr: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Marktwert 1 | 9’355 | 9’660 | 14’852 | 9’610 | 7’407 | 9’177 | - | - |
Unternehmenswert 1 | 8’678 | 8’952 | 14’016 | 8’823 | 6’683 | 8’257 | 8’816 | 8’640 |
KGV | 58.4 x | 78.8 x | 62.9 x | 32.7 x | 25.5 x | 35.1 x | 27.7 x | 24.2 x |
Rendite | 0.62% | 0.46% | 0.54% | 1.02% | 1.33% | 1.04% | 1.2% | 1.35% |
Marktkapitalisierung / Umsatz | 6.41 x | 7.23 x | 9.02 x | 5.05 x | 3.55 x | 4.05 x | 3.6 x | 3.3 x |
Unternehmenswert / Umsatz | 5.95 x | 6.7 x | 8.51 x | 4.64 x | 3.2 x | 3.64 x | 3.46 x | 3.11 x |
Unternehmenswert / EBITDA | 27.3 x | 37.6 x | 32.2 x | 18.9 x | 15.8 x | 18.2 x | 15.5 x | 13.2 x |
Unternehmenswert / FCF | 36.7 x | 67 x | 42.1 x | 60.7 x | 48.8 x | 24.6 x | 32.5 x | 26.8 x |
FCF Yield | 2.73% | 1.49% | 2.37% | 1.65% | 2.05% | 4.07% | 3.08% | 3.74% |
Price to Book | 6.69 x | 6.75 x | 8.95 x | 4.77 x | 3.43 x | 3.92 x | 3.65 x | 3.31 x |
Anz. der Aktien (in Tausend) | 89’441 | 89’441 | 89’441 | 89’441 | 89’441 | 89’441 | - | - |
Referenzkurs 2 | 104.6 | 108.0 | 166.0 | 107.4 | 82.82 | 102.6 | 102.6 | 102.6 |
Datum der Veröffentlichung | 06.12.19 | 12.12.20 | 10.12.21 | 09.12.22 | 12.12.23 | - | - | - |
Ergebnisentwicklung (Jahreszahlen)
Steuerjahr: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Umsatz 1 | 1’459 | 1’335 | 1’647 | 1’903 | 2’089 | 2’267 | 2’551 | 2’778 |
EBITDA 1 | 318.1 | 238 | 435.2 | 466.6 | 422.2 | 454.9 | 569.1 | 654.9 |
Betriebsergebnis (EBIT) 1 | 235 | 177.6 | 373.6 | 396.9 | 348.1 | 364.8 | 471.9 | 545.5 |
Umsatzrendite | 16.1% | 13.3% | 22.69% | 20.86% | 16.66% | 16.09% | 18.5% | 19.64% |
Gewinn vor Steuern (EBT) 1 | 229.9 | 178.7 | 339 | 403.5 | 412.6 | 367.7 | 457.3 | 527.9 |
Nettoergebnis 1 | 159.8 | 122.4 | 236.3 | 293.9 | 290.4 | 257.6 | 325.5 | 373.7 |
Nettomarge | 10.95% | 9.16% | 14.35% | 15.45% | 13.9% | 11.36% | 12.76% | 13.45% |
Gewinn pro Aktie 2 | 1.790 | 1.370 | 2.640 | 3.290 | 3.250 | 2.922 | 3.703 | 4.243 |
Free Cash Flow 1 | 236.6 | 133.5 | 332.5 | 145.4 | 137 | 335.8 | 271.3 | 322.9 |
FCF-Marge N | 16.21% | 10% | 20.19% | 7.64% | 6.56% | 14.81% | 10.63% | 11.63% |
FCF Conversion (EBITDA) | 74.37% | 56.11% | 76.41% | 31.16% | 32.45% | 73.82% | 47.67% | 49.31% |
FCF Conversion (Nettoergebnis) | 148.1% | 109.12% | 140.74% | 49.47% | 47.18% | 130.34% | 83.35% | 86.42% |
Dividende pro Aktie 2 | 0.6500 | 0.5000 | 0.9000 | 1.100 | 1.100 | 1.065 | 1.228 | 1.390 |
Datum der Veröffentlichung | 06.12.19 | 12.12.20 | 10.12.21 | 09.12.22 | 12.12.23 | - | - | - |
Ergebnisentwicklung (Quartalszahlen)
Steuerjahr: September | 2020 S1 | 2021 S1 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz 1 | 714.9 | 767.4 | 410.2 | 445.2 | 855.4 | 477.5 | 569.9 | 470.3 | 504.2 | 974.5 | 535.1 | 579.7 | 475 | 502.5 | 1’010 | 613.1 | 701.5 | 1’345 | - | - |
EBITDA 1 | - | - | - | - | - | - | - | - | 101.9 | - | - | - | - | 69.03 | 158 | 137.7 | 198.5 | 330 | - | - |
Betriebsergebnis (EBIT) 1 | 105.3 | 162.7 | - | 102.9 | 177.3 | 98.58 | 121 | 63.1 | 83.62 | - | 101 | 103.2 | 46 | 54.64 | 106 | 118.7 | 152.3 | 278 | - | - |
Umsatzrendite | 14.73% | 21.2% | - | 23.11% | 20.73% | 20.64% | 21.23% | 13.42% | 16.58% | - | 18.88% | 17.81% | 9.68% | 10.87% | 10.5% | 19.36% | 21.71% | 20.67% | - | - |
Gewinn vor Steuern (EBT) 1 | 96.1 | - | - | 120.1 | - | 88.33 | 141 | - | 90.71 | - | 132.3 | 116.5 | 54.7 | 54.65 | - | 120.7 | 153.8 | - | - | - |
Nettoergebnis 1 | - | - | - | 90.73 | - | 62.53 | 102.7 | - | 62 | - | 92.15 | 85.2 | 37.4 | 38.26 | - | 83.92 | 110.1 | - | - | - |
Nettomarge | - | - | - | 20.38% | - | 13.1% | 18.02% | - | 12.3% | - | 17.22% | 14.7% | 7.87% | 7.61% | - | 13.69% | 15.7% | - | - | - |
Gewinn pro Aktie 2 | - | 1.120 | 0.4200 | 1.020 | - | 0.7000 | 1.150 | 0.5700 | 0.6900 | - | 1.030 | 0.9600 | 0.4200 | 0.4276 | - | 0.9396 | 1.222 | - | - | - |
Dividende pro Aktie 2 | - | - | - | - | - | - | 1.100 | - | - | - | - | 1.100 | - | - | - | - | 1.027 | - | - | - |
Datum der Veröffentlichung | 11.05.20 | 28.05.21 | 11.02.22 | 13.05.22 | 13.05.22 | 05.08.22 | 09.12.22 | 14.02.23 | 15.05.23 | 15.05.23 | 06.08.23 | 12.12.23 | 14.02.24 | - | - | - | - | - | - | - |
Bilanzanalyse
Steuerjahr: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoschuld 1 | - | - | - | - | - | - | - | - |
Nettoliquidität 1 | 678 | 707 | 835 | 787 | 725 | 920 | 361 | 537 |
Verschuldungsgrad (Verbindlichkeiten/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 237 | 134 | 333 | 145 | 137 | 336 | 271 | 323 |
ROE (Nettogewinn/Eigenkapital) | 11.9% | 8.65% | 15.3% | 16% | 13.4% | 11.4% | 13.1% | 13.9% |
ROA (Nettogewinn/Gesamtvermögen) | 8.67% | 6.07% | 10.7% | 11.3% | 9.92% | 7.65% | 8.33% | 8.96% |
Aktiva 1 | 1’842 | 2’016 | 2’205 | 2’609 | 2’928 | 3’368 | 3’908 | 4’168 |
Buchwert je Aktie 2 | 15.60 | 16.00 | 18.60 | 22.50 | 24.10 | 26.10 | 28.10 | 31.00 |
Cash Flow pro Aktie 2 | 2.460 | 2.000 | 4.050 | 2.100 | 2.800 | 3.290 | 4.010 | 4.660 |
Capex 1 | 20.3 | 45 | 30.1 | 82 | 114 | 93.6 | 105 | 114 |
Capex / Umsatz | 1.39% | 3.37% | 1.83% | 4.31% | 5.45% | 4.13% | 4.13% | 4.11% |
Datum der Veröffentlichung | 06.12.19 | 12.12.20 | 10.12.21 | 09.12.22 | 12.12.23 | - | - | - |
Gewinn pro Aktie & Dividende
Historische Entwicklung KGV
Entwicklung der Dividendenrendite
Entwicklung Unternehmenswert / EBITDA
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+2.49% | 9.82 Mrd. | |
+9.16% | 219 Mrd. | |
+8.95% | 187 Mrd. | |
+12.33% | 134 Mrd. | |
+26.83% | 101 Mrd. | |
+0.46% | 62.27 Mrd. | |
+15.62% | 52.82 Mrd. | |
-2.10% | 47.49 Mrd. | |
+0.36% | 40.79 Mrd. | |
+11.89% | 39.35 Mrd. |
- Börse
- Aktien
- 531370 Aktie
- Finanzen Carl Zeiss Meditec AG